Management Team
Leadership TeamBoard of Directors
Advisors
Leadership Team
Douglas Doerfler
President and CEO
Douglas Doerfler has over 25 years experience in the discovery, development and international financing and commercialization of biotechnology products and companies. He joined MaxCyte as its founding President and CEO in June 1999.
Prior to joining MaxCyte, he held senior corporate development and operating responsibilities for PFRM, Inc., a privately owned biotechnology holding company. He was President, Chief Executive Officer and a Director of Immunicon Corporation, a cell-based therapy and diagnostics company. Mr. Doerfler also held various executive positions with Life Technologies that included leading global businesses, mergers and acquisitions and public offerings.
Mr. Doerfler plays an active role as an advocate for the life sciences industry and serves on the Biotechnology Industry Organization's Board of Directors Executive Committee, and Co-Chairs BIO's Capital Formation Committee. He is a member of the Executive Committees of the Maryland High Technology Council and the Alliance for Regenerative Medicine. He is also Chairman of MDBio.
Doug received his B.S. in Finance from the University of Baltimore School of Business and a certificate in Industrial Relations.
President and CEO
Douglas Doerfler has over 25 years experience in the discovery, development and international financing and commercialization of biotechnology products and companies. He joined MaxCyte as its founding President and CEO in June 1999.
Prior to joining MaxCyte, he held senior corporate development and operating responsibilities for PFRM, Inc., a privately owned biotechnology holding company. He was President, Chief Executive Officer and a Director of Immunicon Corporation, a cell-based therapy and diagnostics company. Mr. Doerfler also held various executive positions with Life Technologies that included leading global businesses, mergers and acquisitions and public offerings.
Mr. Doerfler plays an active role as an advocate for the life sciences industry and serves on the Biotechnology Industry Organization's Board of Directors Executive Committee, and Co-Chairs BIO's Capital Formation Committee. He is a member of the Executive Committees of the Maryland High Technology Council and the Alliance for Regenerative Medicine. He is also Chairman of MDBio.
Doug received his B.S. in Finance from the University of Baltimore School of Business and a certificate in Industrial Relations.
Karen A. Donato, Ph.D.
Executive Vice President, Global Business Development & Marketing
Karen A. Donato, Ph.D., joined MaxCyte in 2008 and currently serves as Executive Vice President of Global Business Development & Marketing. Dr. Donato has over fifteen years of experience in sales and marketing of products and services in life sciences, coupled with product and process development experience in biomedical materials and polymers. Prior to joining MaxCyte, Dr. Donato headed up business development for Summit Drug Development Services, a regulatory consulting firm. Earlier, Dr. Donato led an international sales and marketing team at Celsis|In Vitro Technologies, focused on drug discovery tools for ADME-Tox applications. From 1995-2006, Dr. Donato held positions of increasing levels of responsibility in sales and marketing at TherImmune Research Corporation, which was acquired by Gene Logic during her tenure. At TherImmune and Gene Logic Labs, Dr. Donato was instrumental in the establishment of strategic business relationships with major pharmaceutical and biotechnology companies. Dr. Donato has been involved in R&D and manufacturing in engineering positions at Hoechst Celanese, Ethicon (a Johnson & Johnson Company), and DuPont.
Dr. Donato earned a B.S.E. from the University of Pennsylvania and an M.S. and a Ph.D. from Ohio University, all in Chemical Engineering. Dr. Donato also holds three issued patents in drug delivery.
Executive Vice President, Global Business Development & Marketing
Karen A. Donato, Ph.D., joined MaxCyte in 2008 and currently serves as Executive Vice President of Global Business Development & Marketing. Dr. Donato has over fifteen years of experience in sales and marketing of products and services in life sciences, coupled with product and process development experience in biomedical materials and polymers. Prior to joining MaxCyte, Dr. Donato headed up business development for Summit Drug Development Services, a regulatory consulting firm. Earlier, Dr. Donato led an international sales and marketing team at Celsis|In Vitro Technologies, focused on drug discovery tools for ADME-Tox applications. From 1995-2006, Dr. Donato held positions of increasing levels of responsibility in sales and marketing at TherImmune Research Corporation, which was acquired by Gene Logic during her tenure. At TherImmune and Gene Logic Labs, Dr. Donato was instrumental in the establishment of strategic business relationships with major pharmaceutical and biotechnology companies. Dr. Donato has been involved in R&D and manufacturing in engineering positions at Hoechst Celanese, Ethicon (a Johnson & Johnson Company), and DuPont.
Dr. Donato earned a B.S.E. from the University of Pennsylvania and an M.S. and a Ph.D. from Ohio University, all in Chemical Engineering. Dr. Donato also holds three issued patents in drug delivery.
Ronald Holtz
Chief Financial Officer
Ronald Holtz serves as MaxCyte's Chief Financial Officer. During his career, Mr. Holtz has been CFO of both public and private companies and has raised more than $100m in debt and equity capital. Prior to joining MaxCyte, Mr. Holtz was Chief Financial Officer of B2eMarkets, Inc. a privately held software solutions company targeting Global 1000 companies. Mr. Holtz also served as Vice President and Chief Financial Officer of RWD Technologies, Inc., a leading information technology and performance improvement consulting firm. As CFO, Holtz led RWD's highly successful initial public offering and was responsible for finance, acquisitions, business management and analyst/investor relations. Previously, Mr. Holtz was a manager in Ernst & Young LLP's Financial Advisory Services Group. Mr. Holtz is also a founding member of the Robert H. Smith School of Business Finance Advisory Board at the University of Maryland. He earned a Master's of Business Administration in finance from the University of Maryland, a bachelor's of science degree in mathematics from the University of Wisconsin and is a CPA.
Chief Financial Officer
Ronald Holtz serves as MaxCyte's Chief Financial Officer. During his career, Mr. Holtz has been CFO of both public and private companies and has raised more than $100m in debt and equity capital. Prior to joining MaxCyte, Mr. Holtz was Chief Financial Officer of B2eMarkets, Inc. a privately held software solutions company targeting Global 1000 companies. Mr. Holtz also served as Vice President and Chief Financial Officer of RWD Technologies, Inc., a leading information technology and performance improvement consulting firm. As CFO, Holtz led RWD's highly successful initial public offering and was responsible for finance, acquisitions, business management and analyst/investor relations. Previously, Mr. Holtz was a manager in Ernst & Young LLP's Financial Advisory Services Group. Mr. Holtz is also a founding member of the Robert H. Smith School of Business Finance Advisory Board at the University of Maryland. He earned a Master's of Business Administration in finance from the University of Maryland, a bachelor's of science degree in mathematics from the University of Wisconsin and is a CPA.
Madhusudan Peshwa, Ph.D.
Executive Vice President, Cellular Therapies
Madhusudan Peshwa, Ph.D., currently serves as Vice President, Research and Development at MaxCyte, Inc. Most recently, he was Executive Vice President for Research and Development at NewNeural LLC, a start-up stem cell therapy company. Earlier he served as Vice President of Manufacturing and as Vice President of Process Sciences at Dendreon Corporation (NASDAQ: DNDN), where we was responsible for development, characterization and manufacture of an autologous dendritic cell vaccine product from concept to late Phase III pivotal studies. His expertise is in the areas of design, characterization, scale-up and implementation of processes, and cGMP systems in the development of engineered cell and tissue products and for biopharmaceuticals' production.
Dr. Peshwa obtained his Ph.D. in Chemical Engineering from the University of Minnesota and his B.Tech. in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. He is a co-author on over 35 scientific publications and is a co-inventor on five, issued or under review, patent applications.
Mark SchmeizlExecutive Vice President, Cellular Therapies
Madhusudan Peshwa, Ph.D., currently serves as Vice President, Research and Development at MaxCyte, Inc. Most recently, he was Executive Vice President for Research and Development at NewNeural LLC, a start-up stem cell therapy company. Earlier he served as Vice President of Manufacturing and as Vice President of Process Sciences at Dendreon Corporation (NASDAQ: DNDN), where we was responsible for development, characterization and manufacture of an autologous dendritic cell vaccine product from concept to late Phase III pivotal studies. His expertise is in the areas of design, characterization, scale-up and implementation of processes, and cGMP systems in the development of engineered cell and tissue products and for biopharmaceuticals' production.
Dr. Peshwa obtained his Ph.D. in Chemical Engineering from the University of Minnesota and his B.Tech. in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. He is a co-author on over 35 scientific publications and is a co-inventor on five, issued or under review, patent applications.
Vice President, Global Sales
Mark Schmeizl serves as MaxCyte's Vice President of Global Sales. Mr. Schmeizl brings over 20 years sales and marketing experience in drug discovery, genomics, and life science research tools. He has repeatedly built and led highly successful commercial teams for leading life science companies including Aushon BioSystems, Cisbio, Affymetrix, and Perkin Elmer (formerly Packard BioSciences). Most recently, he served as a sales management consultant for Forge 4ward where he helped early phase life science companies map out market penetration strategies and build sales teams. Mr. Schmeizl earned his BS in biology at the University of Connecticut.
Board of Directors
J. Stark Thompson, Ph.D.
Chairman of the Board
Dr. Thompson is the former President and CEO of Life Technologies Inc. (now Invitrogen). Dr. Thompson has over thirty years of experience in life sciences technology development and commercialization. From 1988 to 2000, Dr. Thompson served as President and Chief Executive Officer of Life Technologies Inc. and was on the Executive Committee of its largest shareholder Dexter Corporation. Prior to joining Life Technologies, Dr. Thompson served in multiple positions of increasing responsibility over a period of 21 years at DuPont de Nemours and Co., a diversified chemical company. Dr. Thompson held numerous positions at DuPont de Nemours and Co. such as Business Director of the Clinical Systems Division, Manager of the Instruments Systems Division and Manager of Health Care Business Planning. Dr. Thompson received his B.S. in Chemistry from Muskingum College and Ph.D. in Physiological Chemistry from Ohio State University. Dr. Thompson is currently a member of the executive committees of several educational and non-profit organizations and serves as a member of the Board of Directors of Luminex (Nasdaq:LMNX) and Chairman of the Board of GeneLogic (Nasdaq:GLGC)
Chairman of the Board
Dr. Thompson is the former President and CEO of Life Technologies Inc. (now Invitrogen). Dr. Thompson has over thirty years of experience in life sciences technology development and commercialization. From 1988 to 2000, Dr. Thompson served as President and Chief Executive Officer of Life Technologies Inc. and was on the Executive Committee of its largest shareholder Dexter Corporation. Prior to joining Life Technologies, Dr. Thompson served in multiple positions of increasing responsibility over a period of 21 years at DuPont de Nemours and Co., a diversified chemical company. Dr. Thompson held numerous positions at DuPont de Nemours and Co. such as Business Director of the Clinical Systems Division, Manager of the Instruments Systems Division and Manager of Health Care Business Planning. Dr. Thompson received his B.S. in Chemistry from Muskingum College and Ph.D. in Physiological Chemistry from Ohio State University. Dr. Thompson is currently a member of the executive committees of several educational and non-profit organizations and serves as a member of the Board of Directors of Luminex (Nasdaq:LMNX) and Chairman of the Board of GeneLogic (Nasdaq:GLGC)
Will Brooke
William W. Brooke is Managing Partner of Harbert Venture Partners and oversees Harbert's Life Science investments. He also is a Partner of the Harbinger/Aurora Venture Funds, and has served on their Investment Committee and Members' Advisory Committee. Mr. Brooke has been advising start-up companies for more than twenty years, and currently serves on the boards of AV Holdings (Atherotech), Emageon and MaxCyte. As EVP and board member of Harbert for over ten years, Mr. Brooke initially served as the firm's General Counsel and later as its Chief Operating Officer. Mr. Brooke is a guest lecturer on venture capital at the MBA programs at the University of Alabama and the University of Alabama in Birmingham. Mr. Brooke holds degrees in Law and Business Management from the University of Alabama.
William W. Brooke is Managing Partner of Harbert Venture Partners and oversees Harbert's Life Science investments. He also is a Partner of the Harbinger/Aurora Venture Funds, and has served on their Investment Committee and Members' Advisory Committee. Mr. Brooke has been advising start-up companies for more than twenty years, and currently serves on the boards of AV Holdings (Atherotech), Emageon and MaxCyte. As EVP and board member of Harbert for over ten years, Mr. Brooke initially served as the firm's General Counsel and later as its Chief Operating Officer. Mr. Brooke is a guest lecturer on venture capital at the MBA programs at the University of Alabama and the University of Alabama in Birmingham. Mr. Brooke holds degrees in Law and Business Management from the University of Alabama.
Douglas A. Doerfler
President and CEO
Douglas Doerfler has over 25 years experience in the discovery, development and international financing and commercialization of biotechnology products and companies. He joined MaxCyte as its founding President and CEO in June 1999. Prior to joining MaxCyte, he held senior corporate development and operating responsibilities for PFRM, Inc., a privately owned biotechnology holding company. He was President, Chief Executive Officer and a Director of Immunicon Corporation, a cell-based therapy and diagnostics company. Mr. Doerfler also held various executive positions with Life Technologies that included leading global businesses, mergers and acquisitions and public offerings. Mr. Doerfler plays an active role as an advocate for the life sciences industry and serves on the Biotechnology Industry Organization's Board of Directors Executive Committee, and Co-Chairs BIO's Capital Formation Committee. He is a member of the Executive Committees of the Maryland High Technology Council and the Alliance for Regenerative Medicine. He is also Chairman of MDBio. Doug received his B.S. in Finance from the University of Baltimore School of Business and a certificate in Industrial Relations.
President and CEO
Douglas Doerfler has over 25 years experience in the discovery, development and international financing and commercialization of biotechnology products and companies. He joined MaxCyte as its founding President and CEO in June 1999. Prior to joining MaxCyte, he held senior corporate development and operating responsibilities for PFRM, Inc., a privately owned biotechnology holding company. He was President, Chief Executive Officer and a Director of Immunicon Corporation, a cell-based therapy and diagnostics company. Mr. Doerfler also held various executive positions with Life Technologies that included leading global businesses, mergers and acquisitions and public offerings. Mr. Doerfler plays an active role as an advocate for the life sciences industry and serves on the Biotechnology Industry Organization's Board of Directors Executive Committee, and Co-Chairs BIO's Capital Formation Committee. He is a member of the Executive Committees of the Maryland High Technology Council and the Alliance for Regenerative Medicine. He is also Chairman of MDBio. Doug received his B.S. in Finance from the University of Baltimore School of Business and a certificate in Industrial Relations.
Stanley Erck
Mr. Erck, President and CEO, and Director of IOMAI Corporation, applies his 25 years of management experience in the healthcare and biotechnology industry (Baxter International, Procept and Integrated Genetics) to shepherd the development and commercialization of IOMAI technology. In addition to successfully negotiating major alliances with pharmaceutical and biotechnology companies and bringing products into clinical trials, as CEO he has managed the process of developing companies from private funding through IPO. Mr. Erck received his B.S. from the University of Illinois and an M.B.A. from the University of Chicago.
Mr. Erck, President and CEO, and Director of IOMAI Corporation, applies his 25 years of management experience in the healthcare and biotechnology industry (Baxter International, Procept and Integrated Genetics) to shepherd the development and commercialization of IOMAI technology. In addition to successfully negotiating major alliances with pharmaceutical and biotechnology companies and bringing products into clinical trials, as CEO he has managed the process of developing companies from private funding through IPO. Mr. Erck received his B.S. from the University of Illinois and an M.B.A. from the University of Chicago.
Chris Hegele
Chris Hegele joined Intersouth Partners in 2003. He is a long standing member of the Southeast's venture capital community, having spent nearly 20 years as a general partner with Kitty Hawk Capital, a venture capital firm located in Charlotte, North Carolina. Kitty Hawk was founded in 1980 and manages $100 million in four venture capital funds. Prior to joining Kitty Hawk in 1984, Chris was with Arthur Andersen & Co. in its Small Business Group.
Chris Hegele joined Intersouth Partners in 2003. He is a long standing member of the Southeast's venture capital community, having spent nearly 20 years as a general partner with Kitty Hawk Capital, a venture capital firm located in Charlotte, North Carolina. Kitty Hawk was founded in 1980 and manages $100 million in four venture capital funds. Prior to joining Kitty Hawk in 1984, Chris was with Arthur Andersen & Co. in its Small Business Group.
Arthur M. Mandell
Mr. Mandell joined Prestwick in November 2005 and serves as President and Chief Operating Officer. Mr. Mandell has also served as a Director of the Company since October 2005. Mr. Mandell has over 25 years of healthcare management experience in both the pharmaceutical and biotechnology sectors, with extensive expertise in business development, strategic planning, product development, and commercialization of products and services. Most recently, Mr. Mandell was President, Chief Executive Officer, and a Director of Cellective Therapeutics, Inc., a Maryland-based monoclonal antibody company which was acquired by MedImmune Inc. in October, 2005. Prior to joining Cellective, Mr. Mandell was President, Chief Executive Officer, and still serves as a Director of Stemron Corporation, a therapeutic stem cell start up company in Gaithersburg, Maryland. Prior to joining Stemron Corporation, Mr. Mandell served as Senior Vice President and Chief Business Officer of Human Genome Sciences, Inc. (HGS), in Gaithersburg, Maryland. He was instrumental in aiding HGS' transition from an early stage drug discovery company to a fully integrated biopharmaceutical company. Mr. Mandell began his career in California, where he spent over 13 years in various leadership positions, both domestic and international, at Syntex Corporation in Palo Alto, California. Before the merger of Syntex Corporation and F. Hoffman-La Roche, Mr. Mandell was responsible for the Pacific Sector including all Far East Operations as well as Canada and Mexico. He also has experience in the pharmaceutical/biotechnology service sector in his capacity as Partner and West Coast General Manager for ZS Associates, a healthcare consulting firm headquartered in Evanston, Illinois. Mr. Mandell currently serves as a Director for the Maryland High Technology Council and as a Director for the MdBio organization.
Mr. Mandell joined Prestwick in November 2005 and serves as President and Chief Operating Officer. Mr. Mandell has also served as a Director of the Company since October 2005. Mr. Mandell has over 25 years of healthcare management experience in both the pharmaceutical and biotechnology sectors, with extensive expertise in business development, strategic planning, product development, and commercialization of products and services. Most recently, Mr. Mandell was President, Chief Executive Officer, and a Director of Cellective Therapeutics, Inc., a Maryland-based monoclonal antibody company which was acquired by MedImmune Inc. in October, 2005. Prior to joining Cellective, Mr. Mandell was President, Chief Executive Officer, and still serves as a Director of Stemron Corporation, a therapeutic stem cell start up company in Gaithersburg, Maryland. Prior to joining Stemron Corporation, Mr. Mandell served as Senior Vice President and Chief Business Officer of Human Genome Sciences, Inc. (HGS), in Gaithersburg, Maryland. He was instrumental in aiding HGS' transition from an early stage drug discovery company to a fully integrated biopharmaceutical company. Mr. Mandell began his career in California, where he spent over 13 years in various leadership positions, both domestic and international, at Syntex Corporation in Palo Alto, California. Before the merger of Syntex Corporation and F. Hoffman-La Roche, Mr. Mandell was responsible for the Pacific Sector including all Far East Operations as well as Canada and Mexico. He also has experience in the pharmaceutical/biotechnology service sector in his capacity as Partner and West Coast General Manager for ZS Associates, a healthcare consulting firm headquartered in Evanston, Illinois. Mr. Mandell currently serves as a Director for the Maryland High Technology Council and as a Director for the MdBio organization.
David Pierson
David Pierson brings 12 years of pharmaceutical industry experience to Intersouth Partners, where he works with the life science investment team. David joined Intersouth in early 2005 from New Jersey-based NPS Pharmaceuticals, where he built and launched the company's first specialty field sales organization. Prior to NPS, he was director of global marketing for Pharmacia Corporation's oncology franchise, managing the company's portfolio of branded oncology drugs in Europe and Latin America. He began his pharmaceutical career at Johnson & Johnson, advancing through a variety of sales and marketing management roles from managing sales territories to evaluating in-licensing and acquisition opportunities to launching marketing plans for new drugs in the U.S. David holds a B.S. from the United States Military Academy and an M.B.A. from Duke University.
A. Sinclair Dunlop David Pierson brings 12 years of pharmaceutical industry experience to Intersouth Partners, where he works with the life science investment team. David joined Intersouth in early 2005 from New Jersey-based NPS Pharmaceuticals, where he built and launched the company's first specialty field sales organization. Prior to NPS, he was director of global marketing for Pharmacia Corporation's oncology franchise, managing the company's portfolio of branded oncology drugs in Europe and Latin America. He began his pharmaceutical career at Johnson & Johnson, advancing through a variety of sales and marketing management roles from managing sales territories to evaluating in-licensing and acquisition opportunities to launching marketing plans for new drugs in the U.S. David holds a B.S. from the United States Military Academy and an M.B.A. from Duke University.
Mr. Dunlop has almost two decades of international experience in evaluating early-stage biotechnology companies. As the Founder and Managing Partner of MASA Life Science Ventures he leads the review and analysis of Fund investment candidates. A former international business and economics analyst with the Center for Strategic & International Studies in Washington, D.C., Mr. Dunlop has private equity and venture capital experience in East Asia, Europe, the U.S. and Israel. Mr. Dunlop received his M.B.A. from Columbia Business School where he was the R.C. Kopf British-American Fellow in international business. He also holds an M.A. with Honors in Political Economy from the University of Glasgow and an M.A. in International Relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University. Mr. Dunlop currently serves on the Boards of Engene Inc., Mediquest Therapeutics Inc., MaxCyte Inc. and Potentia Pharmaceuticals Inc.
Advisors
Michael R. Blaese, M.D.
Formerly National Institutes of Health
Dr. Blaese was on the faculty of the National Institutes of Health for 33 years where his work spanned a range of areas from basic research in immunology, virology, cancer and molecular genetics to clinical investigation and the development of innovative new therapies. In 1984 he started work to develop the use of genes as medicines that ultimately led to the first successful human gene therapy in 1990. As Chief of Clinical Gene Therapy for the Human Genome Institute, Mike continued to lead the early development of gene therapy introducing clinical trials for inherited immunodeficiency, brain cancer and AIDS. He has served widely on Biotech SABs and government advisory committees and in 1999 he joined Kimeragen (later ValiGen) as Chief Scientific Officer and President of their Molecular Pharmaceuticals Division. He has published over 340 original research papers, holds 11 patents and was instrumental in policy formation governing gene technology in the U.S. at the NIH, FDA and the RAC (Recombinant DNA Advisory Committee) as well as consulting on these topics for the Parliaments of France and Denmark. Most recently Dr. Blaese serves as Research Director of the Fund for Inherited Disease Research, Founder and President of PreGentis and as Medical Director of the Immune Deficiency Foundation.
Formerly National Institutes of Health
Dr. Blaese was on the faculty of the National Institutes of Health for 33 years where his work spanned a range of areas from basic research in immunology, virology, cancer and molecular genetics to clinical investigation and the development of innovative new therapies. In 1984 he started work to develop the use of genes as medicines that ultimately led to the first successful human gene therapy in 1990. As Chief of Clinical Gene Therapy for the Human Genome Institute, Mike continued to lead the early development of gene therapy introducing clinical trials for inherited immunodeficiency, brain cancer and AIDS. He has served widely on Biotech SABs and government advisory committees and in 1999 he joined Kimeragen (later ValiGen) as Chief Scientific Officer and President of their Molecular Pharmaceuticals Division. He has published over 340 original research papers, holds 11 patents and was instrumental in policy formation governing gene technology in the U.S. at the NIH, FDA and the RAC (Recombinant DNA Advisory Committee) as well as consulting on these topics for the Parliaments of France and Denmark. Most recently Dr. Blaese serves as Research Director of the Fund for Inherited Disease Research, Founder and President of PreGentis and as Medical Director of the Immune Deficiency Foundation.
Robert Gerety, M.D., Ph.D.
MEND (Medicine in Need)
With 15 years of experience at the Food and Drug Administration (FDA) and the National Institutes of Health and 14 years as an executive in the pharmaceutical and biotechnology industries, Dr. Gerety brings a wealth of experience to his position as Vice President and Principal Fellow with Nektar. While with the FDA, Dr. Gerety served as associate director for medicine and science and chief of the infectious disease branch at the Office for Biologics Evaluation and Research. Dr. Gerety also has held executive positions in regulatory affairs and research and development at several pharmaceutical companies. Prior to joining Inhale Therapeutics Systems, Dr. Gerety was vice president of development and regulatory affairs at OraVax, Inc. a biotechnology company engaged in the discovery and development of vaccines and antibody products. At Merck & Co., he directed the licensing of the first recombinant human vaccine against hepatitis B and establishing Shionogi as the Japanese commercialization partner. As vice president of development operations at Biogen, Inc., he was instrumental in championing the development of AVONEX¨ (interferon beta-1a), the leading drug used in the treatment of multiple sclerosis. Dr. Gerety was executive vice president and later CEO of ImmuLogic Pharmaceutical Corporation. Dr. Gerety has been a member of the United States Public Health Service, the National Vaccine Advisory Committee of the U.S. government, US Japan Scientific collaboration of Hepatitis, and the AIDS Task Force and has served as a consultant to the NIAID, the NCI, the U.S. Army, the American Red Cross, and the World Health Organization. He received his MA and PhD from Stanford University Medical School and his MD from the George Washington University School of Medicine.
MEND (Medicine in Need)
With 15 years of experience at the Food and Drug Administration (FDA) and the National Institutes of Health and 14 years as an executive in the pharmaceutical and biotechnology industries, Dr. Gerety brings a wealth of experience to his position as Vice President and Principal Fellow with Nektar. While with the FDA, Dr. Gerety served as associate director for medicine and science and chief of the infectious disease branch at the Office for Biologics Evaluation and Research. Dr. Gerety also has held executive positions in regulatory affairs and research and development at several pharmaceutical companies. Prior to joining Inhale Therapeutics Systems, Dr. Gerety was vice president of development and regulatory affairs at OraVax, Inc. a biotechnology company engaged in the discovery and development of vaccines and antibody products. At Merck & Co., he directed the licensing of the first recombinant human vaccine against hepatitis B and establishing Shionogi as the Japanese commercialization partner. As vice president of development operations at Biogen, Inc., he was instrumental in championing the development of AVONEX¨ (interferon beta-1a), the leading drug used in the treatment of multiple sclerosis. Dr. Gerety was executive vice president and later CEO of ImmuLogic Pharmaceutical Corporation. Dr. Gerety has been a member of the United States Public Health Service, the National Vaccine Advisory Committee of the U.S. government, US Japan Scientific collaboration of Hepatitis, and the AIDS Task Force and has served as a consultant to the NIAID, the NCI, the U.S. Army, the American Red Cross, and the World Health Organization. He received his MA and PhD from Stanford University Medical School and his MD from the George Washington University School of Medicine.
Carl June, M.D.
University of Pennsylvania
Carl H. June, M.D., currently serves as Professor, Department of Pathology and Laboratory Medicine and Director, Translational Research Programs at the Abramson Cancer Center, University of Pennsylvania School of Medicine. Dr. June is a 1975 graduate of the Naval Academy in Annapolis, and a graduate of Baylor College of Medicine in Houston, 1979. He had graduate training in Immunology at the World Health Organization, Geneva, Switzerland from 1978-79, and post-doctoral training in transplantation biology at the Fred Hutchinson Cancer Research Center in Seattle from 1983 Ð 1986. He is board certified in Internal Medicine and Medical Oncology. He was a faculty member in the Departments of Medicine and Cell and Molecular Biology at the Uniformed Services University for the Health Sciences in Bethesda from 1987 to 1998. He is a member of the American Academy of Physicians, and a recipient of the Bristol Myers Squibb Freedom to Discover Award. Since moving to the University of Pennsylvania in 1999 as a Professor of Pathology and Laboratory Medicine, Dr. June has established a facility to produce experimental cell based therapeutics. Currently, Dr. June is involved with several clinical trials that are testing various forms of cell based therapies for cancer and HIV infection. Dr. June is the scientific founder of Xcyte Therapies, Inc.
University of Pennsylvania
Carl H. June, M.D., currently serves as Professor, Department of Pathology and Laboratory Medicine and Director, Translational Research Programs at the Abramson Cancer Center, University of Pennsylvania School of Medicine. Dr. June is a 1975 graduate of the Naval Academy in Annapolis, and a graduate of Baylor College of Medicine in Houston, 1979. He had graduate training in Immunology at the World Health Organization, Geneva, Switzerland from 1978-79, and post-doctoral training in transplantation biology at the Fred Hutchinson Cancer Research Center in Seattle from 1983 Ð 1986. He is board certified in Internal Medicine and Medical Oncology. He was a faculty member in the Departments of Medicine and Cell and Molecular Biology at the Uniformed Services University for the Health Sciences in Bethesda from 1987 to 1998. He is a member of the American Academy of Physicians, and a recipient of the Bristol Myers Squibb Freedom to Discover Award. Since moving to the University of Pennsylvania in 1999 as a Professor of Pathology and Laboratory Medicine, Dr. June has established a facility to produce experimental cell based therapeutics. Currently, Dr. June is involved with several clinical trials that are testing various forms of cell based therapies for cancer and HIV infection. Dr. June is the scientific founder of Xcyte Therapies, Inc.
James Weaver, Ph.D.
Massachusetts Institute of Technology
James C. Weaver, Ph.D., is a Senior Research Scientist in the Harvard-MIT Division of Health Sciences and Technology on the MIT campus. Dr. Weaver has published more than one hundred peer-reviewed scientific papers, has twenty-four issued patents, and in 2000 was elected Fellow of the American Institute for Medical and Biological Engineering. His research has emphasized electromagnetic field effects in cells and tissues, with a focus on the fundamental mechanism of cell electroporation and its biomedical applications. Dr. Weaver received his BA from Carleton College, and MS and PhD degrees in Physics from Yale University.
John Reardon, Ph.D. Massachusetts Institute of Technology
James C. Weaver, Ph.D., is a Senior Research Scientist in the Harvard-MIT Division of Health Sciences and Technology on the MIT campus. Dr. Weaver has published more than one hundred peer-reviewed scientific papers, has twenty-four issued patents, and in 2000 was elected Fellow of the American Institute for Medical and Biological Engineering. His research has emphasized electromagnetic field effects in cells and tissues, with a focus on the fundamental mechanism of cell electroporation and its biomedical applications. Dr. Weaver received his BA from Carleton College, and MS and PhD degrees in Physics from Yale University.
Integrated Oncology Solutions, Inc.
John E Reardon is the Executive Vice President and Chief Scientific Officer at Integrated Oncology Solutions, Inc., a biopharmaceutical company headquartered in Research Triangle Park, NC. Prior to joining IOS Dr. Reardon was the Senior Vice President of Discovery Research Biology at GlaxoSmithKline with responsibility for the majority of biological science supporting gene-to-function-to-target-to-lead activities in the international GSK R&D organization. Dr. Reardon received his Ph.D. degree in Chemistry from The Ohio State University and did post-doctoral research with Dr. Robert Abeles at Brandeis University before beginning a career in the pharmaceutical industry. He joined Burroughs Wellcome Co. in 1987 as a Research Scientist where he contributed to the discovery and development of several anti-viral compounds.